• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

The CHARM-Alternative trial: Angiotensin-receptor blockers in heart failure [Classics Series]

byAndrew Cheung, MD MBA
July 7, 2013
in General Medicine Classics, The Classics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. Candesartan significantly reduced cardiovascular death and hospital admission for chronic heart failure in patients with heart failure and reduced ventricular function, who were intolerant to ACE inhibitors.

2. Candesartan was well-tolerated in patients with previous intolerance to ACE inhibitors.

Original Date of Publication: September 6, 2003

Study Rundown: Angiotensin-converting-enzyme (ACE) inhibitors have been shown to effectively reduce morbidity and mortality in patients with symptomatic heart failure, but intolerance to ACE inhibitors occurs frequently. Angiotensin-receptor blockers (ARB) are an alternative agent that may be used to inhibit the renin-angiotensin-aldosterone system but evidence of its effectiveness in reducing long-term clinical events was limited at the time this study was conducted. The CHARM-Alternative trial was one arm of the CHARM-Overall programme assessing the effectiveness of candesartan compared to placebo in patients with symptomatic heart failure and reduced left-ventricular systolic function, who could not tolerate ACE inhibitors. Results of the study showed a significant reduction in cardiovascular death and hospital admission due to heart failure in the candesartan group.

In sum, an angiotensin receptor blocker should be considered in patients with symptomatic chronic heart failure, reduced ventricular function, and an intolerance to ACE inhibitors.

Please click to read study in The Lancet

RELATED REPORTS

Days alive out of hospital after ventricular assist device implantation vary with comorbidity status

NT-proBNP associated with risk for incident heart failure and all-cause mortality

#VisualAbstract: Moderately accelerated cardiac pacing may be beneficial in patients with heart failure with preserved ejection fraction

In-Depth [randomized, controlled study]: Published in The Lancet in 2003, this study randomized 2,028 patients to receive an ARB (i.e., candesartan) or placebo and investigated the long-term clinical outcomes. The CHARM-Alternative trial included patients with symptomatic chronic heart failure (CHF) and left-ventricular ejection fraction of 40% or less who had a previously documented intolerance to ACE inhibitors. The primary outcome of cardiovascular death or hospital admission for CHF occurred in 33% of patients in the candesartan group and 40% of patients in the placebo group. This reduction in the primary outcome in the candesartan group was significant and was maintained when non-fatal myocardial infarction, non-fatal stroke and coronary revascularization were included in the composite outcome. Study drug discontinuation was similar between the treatment and placebo groups suggesting that candesartan was well-tolerated in this population of patients in spite of previously documented intolerance to ACE-inhibitors.

By Adrienne Cheung, Andrew Cheung, M.D.

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain.

Tags: ACE inhibitorsAngiotensinCHARMheart failure
Previous Post

Mortality risk higher in pediatric trauma patients with chronic conditions

Next Post

Severe endometriosis associated with poor IVF outcomes

RelatedReports

Mesenchymal precursor cell transplant did not improve weaning from device support in LVAD patients
Cardiology

Days alive out of hospital after ventricular assist device implantation vary with comorbidity status

February 24, 2023
Quick Take: Association of African Ancestry with Electrocardiographic Voltage and Concentric Left Ventricular Hypertrophy: The Dallas Heart Study
Cardiology

NT-proBNP associated with risk for incident heart failure and all-cause mortality

February 19, 2023
StudyGraphics

#VisualAbstract: Moderately accelerated cardiac pacing may be beneficial in patients with heart failure with preserved ejection fraction

February 15, 2023
Remote patient monitoring did not reduce heart failure readmissions: The BEAT-HF trial
Cardiology

Anthracycline may be associated with increased incidence of heart failure

February 10, 2023
Next Post
Severe endometriosis associated with poor IVF outcomes

Severe endometriosis associated with poor IVF outcomes

Reduced HPV vaccine doses may be adequate

Low incidence and high clearance of oral HPV infections in men

Half of parents aware of CT radiation cancer risk

Half of parents aware of CT radiation cancer risk

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Abnormal menstruation may be associated with worse cardiometabolic outcomes later in life
  • Past infection with pre-omicron variants of COVID-19 protects against re-infection
  • No difference in complete expulsion of intrauterine device between early and standard interval postpartum placement
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options